Cross posted from Nature’s The Great Beyond blog. Advanced Cell Technology of Worcester, Massachusetts announced on Tuesday a human embryonic stem cell therapy it really is developing for a uncommon type of juvenile blindness offers been granted orphan drug status by the united states Food and Drug Administration . The unique status gives companies taxes breaks, usage of grant funding for clinical trials, or more to seven years of market exclusivity under the 1983 Orphan Medication Act. The Action is aimed at speeding therapies for illnesses afflicting less than 200,000 People in america. Read the remaining post on THE FANTASTIC Beyond.Efficacy The median progression-free survival was 25.2 months with MPT.72; 95 percent confidence interval [CI], 0.61 to 0.85; P<0.).70; 95 percent CI, 0.60 to 0.82; P<0.001) .03; 95 percent CI, 0.89 to at least one 1.20; P=0.70). Although the difference in general survival did not cross the prespecified superiority boundary . S2 and S3 in the Supplementary Appendix).001 for both comparisons) . S4 in the Supplementary Appendix). S5 in the Supplementary Appendix).5 months, P<0.001) or with MPT .9 months vs. 36.3 months; hazard ratio for progression or loss of life, 0.78; P=0.005) .